Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
VITALTE LIFESCIENCES INC. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. OLGA V TCHERKASSKAYA is the busiest examiner for the portfolio with 1 pending action. With 3 pending office actions, the company is actively pursuing patent protection for its biotechnology and pharmaceutical innovations.
The distribution across 3 distinct art units and 3 distinct examiners indicates that each application is being reviewed by a different expert in a different specialized field. This level of dispersion for a small portfolio suggests that the company's research spans several distinct areas of biotechnology. Managing 3 pending office actions across 3 different art units requires the company to adapt to a variety of specialized examination practices and technical requirements. The involvement of 3 distinct examiners means that the company must address unique sets of examiner preferences and styles, reflecting the diverse nature of its current patent filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| SHAH, NILAY J | 1 | 76.3% | +46.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19059219 | MICROSPHERE PRODUCTION METHOD | TCHERKASSKAYA, OLGA V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19059219 | MICROSPHERE PRODUCTION METHOD | TCHERKASSKAYA, OLGA V | — |
| 17588147 | MINIMALLY TRAUMATIC TROCAR APPARATUS AND KIT FOR SUBCUTANEOUS MEDICATION DELIVERY | SHAH, NILAY J | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19059219 | MICROSPHERE PRODUCTION METHOD | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Non-Final OA | — | Pending | Feb 20, 2025 |
| 17588147 | MINIMALLY TRAUMATIC TROCAR APPARATUS AND KIT FOR SUBCUTANEOUS MEDICATION DELIVERY | SHAH, NILAY J | 3783 | §103 | Non-Final OA | — | Pending | Jan 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVITALTE LIFESCIENCES INC. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Olga V Tcherkasskaya has the most, with 1 of VITALTE LIFESCIENCES INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
